MACROGENICS, INC. Increase (Decrease) in Accounts Payable
MACROGENICS, INC. (MGNX) reported Increase (Decrease) in Accounts Payable of -$280.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-03-09
- MACROGENICS, INC. increase (decrease) in accounts payable for the quarter ending 2017-06-30 was $197.00K, a 496.97% increase year-over-year.
- MACROGENICS, INC. increase (decrease) in accounts payable for the quarter ending 2017-03-31 was -$2.22M.
- MACROGENICS, INC. increase (decrease) in accounts payable for the quarter ending 2016-12-31 was $2.37M.
- MACROGENICS, INC. increase (decrease) in accounts payable for the quarter ending 2016-09-30 was $222.00K, a 67.73% decline year-over-year.
- MACROGENICS, INC. increase (decrease) in accounts payable for fiscal 2025 was -$280.00K.
- MACROGENICS, INC. increase (decrease) in accounts payable for fiscal 2024 was -$1.53M, a 219.44% decline from fiscal 2023.
- MACROGENICS, INC. increase (decrease) in accounts payable for fiscal 2023 was $1.28M.
- MACROGENICS, INC. increase (decrease) in accounts payable for fiscal 2022 was -$10.86M, a 252.42% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 3 month as first filed | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 9 month as first filed | Increase (Decrease) in Accounts Payable 12 month | Increase (Decrease) in Accounts Payable 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | -$280.00K 10-K · filed 2026-03-09 | ||||||
| 2024-12-31 | -$1.53M 10-K · filed 2026-03-09 | ||||||
| 2023-12-31 | $1.28M 10-K · filed 2026-03-09 | ||||||
| 2022-12-31 | -$10.86M 10-K · filed 2025-03-20 | ||||||
| 2021-12-31 | $7.13M 10-K · filed 2024-03-07 | ||||||
| 2020-12-31 | $3.72M 10-K · filed 2023-03-15 | ||||||
| 2019-12-31 | $787.00K 10-K · filed 2022-02-24 | ||||||
| 2018-12-31 | $1.55M 10-K · filed 2021-02-25 | ||||||
| 2017-12-31 | -$1.54M 10-K · filed 2020-02-25 | ||||||
| 2017-06-30 | $197.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | -$2.03M 10-Q · filed 2017-08-02 | $339.00K derived: sum of 3 quarters · filed 2019-02-26 | $561.00K derived: sum of 4 quarters · filed 2019-02-26 | |||
| 2017-03-31 | -$2.22M 10-Q · filed 2017-05-03 | $142.00K derived: sum of 2 quarters · filed 2019-02-26 | $364.00K derived: sum of 3 quarters · filed 2019-02-26 | $397.00K derived: sum of 4 quarters · filed 2019-02-26 | |||
| 2016-12-31 | $2.37M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $2.59M derived: sum of 2 quarters · filed 2019-02-26 | $2.62M derived: sum of 3 quarters · filed 2019-02-26 | $2.23M 10-K · filed 2019-02-26 | |||
| 2016-09-30 | $222.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02 | $255.00K derived: sum of 2 quarters · filed 2017-08-02 | -$133.00K 10-Q · filed 2016-11-02 | -$1.17M derived: sum of 4 quarters · filed 2018-02-27 | |||
| 2016-06-30 | $33.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | -$355.00K 10-Q · filed 2017-08-02 | -$1.39M derived: sum of 3 quarters · filed 2018-02-27 | -$702.00K derived: sum of 4 quarters · filed 2018-02-27 | |||
| 2016-03-31 | -$388.00K 10-Q · filed 2017-05-03 | -$1.42M derived: sum of 2 quarters · filed 2018-02-27 | -$735.00K derived: sum of 3 quarters · filed 2018-02-27 | -$326.00K derived: sum of 4 quarters · filed 2018-02-27 | |||
| 2015-12-31 | -$1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | -$347.00K derived: sum of 2 quarters · filed 2018-02-27 | $62.00K derived: sum of 3 quarters · filed 2018-02-27 | -$163.00K 10-K · filed 2018-02-27 | |||
| 2015-09-30 | $688.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02 | $1.10M derived: sum of 2 quarters · filed 2016-11-02 | $872.00K 10-Q · filed 2016-11-02 | -$1.85M derived: sum of 4 quarters · filed 2017-02-28 | |||
| 2015-06-30 | $409.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | $184.00K 10-Q · filed 2016-08-03 | -$2.54M derived: sum of 3 quarters · filed 2017-02-28 | -$2.12M derived: sum of 4 quarters · filed 2017-02-28 | |||
| 2015-03-31 | -$225.00K 10-Q · filed 2016-05-04 | -$2.94M derived: sum of 2 quarters · filed 2017-02-28 | -$2.53M derived: sum of 3 quarters · filed 2017-02-28 | -$3.69M derived: sum of 4 quarters · filed 2017-02-28 | |||
| 2014-12-31 | -$2.72M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | -$2.31M derived: sum of 2 quarters · filed 2017-02-28 | -$3.46M derived: sum of 3 quarters · filed 2017-02-28 | -$1.50M 10-K · filed 2017-02-28 | |||
| 2014-09-30 | $411.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | -$745.00K derived: sum of 2 quarters · filed 2015-11-04 | $1.22M 10-Q · filed 2015-11-04 | $2.59M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2014-06-30 | -$1.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | $808.00K 10-Q · filed 2015-08-05 | $2.18M derived: sum of 3 quarters · filed 2016-02-29 | $1.86M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2014-03-31 | $1.96M 10-Q · filed 2015-05-06 | $1.96M 10-Q · filed 2014-05-06 | $3.33M derived: sum of 2 quarters · filed 2016-02-29 | $3.01M derived: sum of 3 quarters · filed 2016-02-29 | $2.34M derived: sum of 4 quarters · filed 2016-02-29 | ||
| 2013-12-31 | $1.37M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $1.05M derived: sum of 2 quarters · filed 2016-02-29 | $374.90K derived: sum of 3 quarters · filed 2016-02-29 | -$570.00K 10-K · filed 2016-02-29 | -$570.09K 10-K · filed 2014-03-20 | ||
| 2013-09-30 | -$321.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | -$996.10K derived: sum of 2 quarters · filed 2014-11-12 | -$1.94M 10-Q · filed 2014-11-12 | -$1.94M 10-Q · filed 2013-11-12 | -$3.81M derived: sum of 4 quarters · filed 2015-03-03 | ||
| 2013-06-30 | -$675.10K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | -$1.62M 10-Q · filed 2014-08-05 | -$3.49M derived: sum of 3 quarters · filed 2015-03-03 | ||||
| 2013-03-31 | -$944.90K 10-Q · filed 2014-05-06 | -$2.81M derived: sum of 2 quarters · filed 2015-03-03 | |||||
| 2012-12-31 | -$1.87M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-03 | -$7.31M 10-K · filed 2015-03-03 | -$7.31M 10-K · filed 2014-03-20 | ||||
| 2012-09-30 | -$5.44M 10-Q · filed 2013-11-12 | ||||||
| 2011-12-31 | -$10.27M 10-K · filed 2014-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |